Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Alexander Astrakhan"'
Autor:
Biswajit Paul, Guillermo S. Romano Ibarra, Nicholas Hubbard, Teresa Einhaus, Alexander Astrakhan, David J. Rawlings, Hans-Peter Kiem, Christopher W. Peterson
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 9, Iss , Pp 347-357 (2018)
Targeted gene therapy strategies utilizing homology-driven repair (HDR) allow for greater control over transgene integration site, copy number, and expression—significant advantages over traditional vector-mediated gene therapy with random genome i
Externí odkaz:
https://doaj.org/article/56114474240942e3a1fa2e4c6ae52ebb
Autor:
Malika Hale, Baeckseung Lee, Yuchi Honaker, Wai-Hang Leung, Alexandra E. Grier, Holly M. Jacobs, Karen Sommer, Jaya Sahni, Shaun W. Jackson, Andrew M. Scharenberg, Alexander Astrakhan, David J. Rawlings
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 4, Iss C, Pp 192-203 (2017)
Gene editing by homology-directed recombination (HDR) can be used to couple delivery of a therapeutic gene cassette with targeted genomic modifications to generate engineered human T cells with clinically useful profiles. Here, we explore the functio
Externí odkaz:
https://doaj.org/article/5c8a965f6c324b0c809e18b4b234bc06
Autor:
Guillermo S Romano Ibarra, Biswajit Paul, Blythe D Sather, Patrick M Younan, Karen Sommer, John P Kowalski, Malika Hale, Barry Stoddard, Jordan Jarjour, Alexander Astrakhan, Hans-Peter Kiem, David J Rawlings
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 5, Iss C (2016)
A naturally occurring 32-base pair deletion of the HIV-1 co-receptor CCR5 has demonstrated protection against HIV infection of human CD4+ T cells. Recent genetic engineering approaches using engineered nucleases to disrupt the gene and mimic this mut
Externí odkaz:
https://doaj.org/article/9a753dd3c9794ca9b239d6c43c9c7b98
Autor:
Michael Certo, Christopher Baldeviano, Sharlene Adams, Martin Asimis, Alexander Astrakhan, Andy Chavkin, Maria L. Cabral, Jimmy Chu, Marie Debrue, Devina Desai, John Evans, Pinky Htun, Amanda Iniguez, Jordan Jarjour, Carl Johnson, Harini Kantamneni, Sema Kurtulus, Michael Magee, Unja Martin, Seamus McKenney, Sara Miller, Prashant Nambiar, Vinh Khang Nguyen, Mauris Nnamani, Jen Obrigewitch, Lisa Pechilis, Molly Perkins, Christopher Petersen, Jason Pinger, Cindy Rogers, Nick Rouillard, Kendal Sanson, Emily Thompson, Collin Walter, Roslyn Yi, Sarah Voytek, Philip Gregory
Publikováno v:
Cancer Research. 82:581-581
Anti-CD19 CAR T cell therapies have improved outcomes for non-Hodgkin lymphoma (NHL) patients. However, only 30-40% of patients treated with commercially available CART cell therapies obtain long term remission, highlighting the need for more efficac
Autor:
Danielle Montt, Rachael Logan, Timmer John C, Mark Pogson, Jordan Jarjour, Claudya Evandy, Jones Kyle S, Giacomo Tampella, Quennie Vong, Anne-Rachael Krostag, Joshua A. Gustafson, Dong Xia, Alexander Astrakhan, Kaori Oda, Bryan Peguero, Wai-Hang Leung, Jacob Appelbaum, Brendan Eckelman, Joy Zhang, Michael C. Jensen, James B. Rottman, Unja Martin
Publikováno v:
Regular and young investigator award abstracts.
Background Bioengineered T cell treatments for acute myeloid leukemia (AML) are challenged by near universal expression of leukemia antigens on normal hematopoietic stem/progenitor cells:1 2 ‘on target/off tumor‘ activity may cause myelosuppressi
Autor:
Jacob S. Appelbaum, April Price, Joy Zhang, Kaori Oda, Sumati Sundaram, Paula Lewis, Sanela Bilic, Giacomo Tampella, Dong Xia, Anne-Rachel Krostag, Pauline So, Unja Martin, Wai-Hang Leung, Alexander Astrakhan, Mark Pogson, Jordan Jarjour, Josh Gustafson, Michael CV Jensen
Publikováno v:
Blood. 138:905-905
Background: Acute myeloid leukemia (AML) chimeric antigen receptor (CAR) T cell therapies are at early stages of testing in human clinical trials. We previously described the design of a CD33-specific dimerizing agent regulated immunoreceptor complex
Autor:
Wai-Hang Leung, Joel Gay, Unja Martin, Tracy E. Garrett, Holly M. Horton, Michael T. Certo, Bruce R. Blazar, Richard A. Morgan, Philip D. Gregory, Jordan Jarjour, Alexander Astrakhan
Publikováno v:
JCI insight. 5
Chimeric antigen receptor (CAR) T cell therapies have achieved promising outcomes in several cancers, however more challenging oncology indications may necessitate advanced antigen receptor designs and functions. Here we describe a bipartite receptor
Autor:
Nicholas Hubbard, David J. Rawlings, Teresa Einhaus, Christopher W. Peterson, Biswajit Paul, Hans-Peter Kiem, Guillermo S. Romano Ibarra, Alexander Astrakhan
Publikováno v:
Molecular Therapy. Methods & Clinical Development
Molecular Therapy: Methods & Clinical Development, Vol 9, Iss, Pp 347-357 (2018)
Molecular Therapy: Methods & Clinical Development, Vol 9, Iss, Pp 347-357 (2018)
Targeted gene therapy strategies utilizing homology-driven repair (HDR) allow for greater control over transgene integration site, copy number, and expression—significant advantages over traditional vector-mediated gene therapy with random genome i
Autor:
Shannon Grande, Kathryn Hooper, Yegor Smurnyy, Andrew Chavkin, Ankit Gupta, Richard A. Morgan, Unja Martin, Michael S Magee, Jordan Jarjour, Lisa J Pechilis, Amanda Rode, Anne-Rachel Krostag, Kyle Havens, Alexander Astrakhan
Publikováno v:
Blood. 132:338-338
Chimeric antigen receptor (CAR) T cell therapies continue to show excellent outcomes in hematological cancers. Achieving success in additional tumor indications, however, will likely require modulating inhibitory pathways that limit CAR T cell potenc
Autor:
Wai-Hang Leung, Alexandra E. Grier, David J. Rawlings, Andrew M. Scharenberg, Honaker Yuchi Chiang, Alexander Astrakhan, Jaya Sahni, Baeckseung Lee, Holly M. Jacobs, Malika Hale, Karen Sommer, Shaun W. Jackson
Publikováno v:
Molecular Therapy. Methods & Clinical Development
Molecular Therapy: Methods & Clinical Development, Vol 4, Iss C, Pp 192-203 (2017)
Molecular Therapy: Methods & Clinical Development, Vol 4, Iss C, Pp 192-203 (2017)
Gene editing by homology-directed recombination (HDR) can be used to couple delivery of a therapeutic gene cassette with targeted genomic modifications to generate engineered human T cells with clinically useful profiles. Here, we explore the functio